Anzeige
Mehr »
Login
Mittwoch, 15.01.2025 Börsentäglich über 12.000 News von 681 internationalen Medien
Löst diese riesige Entdeckung die Kupferkrise der KI? So ändert sich die Rechnung durch diesen Explorer!!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
GlobeNewswire (Europe)
86 Leser
Artikel bewerten:
(0)

Parks! America, Inc. Reports Fiscal Year 2024 Financial Results

Finanznachrichten News

Management to host conference call on Monday, December 16, 2024, at 4:30 PM ET

PINE MOUNTAIN, Georgia, Dec. 13, 2024 (GLOBE NEWSWIRE) -- Parks! America, Inc. (OTCPink: PRKA), today announced its financial results for fiscal year 2024 ended September 29, 2024. The summary information in this press release should not be used as the sole basis for making investment decisions. We encourage shareholders to read our complete Annual Report on Form 10-K, which has been posted on the Company's website animalsafari.com/investor-relations, for a complete view of the Company and its results.

Fiscal Year 2024 Segment Financial Results

The Company manages its operations on an individual location basis. Financial information regarding each of the Company's reportable segments are summarized in the tables below.

For the three months ended For the year ended
September 29, 2024 October 1, 2023 September 29, 2024 October 1, 2023
Total revenues:
Georgia $1,471,131 $1,770,394 $5,960,259 $5,873,526
Missouri 718,543 631,285 2,036,280 1,692,765
Texas 418,017 451,593 1,915,721 1,873,957
Consolidated $2,607,691 $2,853,272 $9,912,260 $9,440,248
Income (loss) before income taxes:
Georgia $570,862 $689,362 $2,294,879 $2,054,001
Missouri 290,333 227,281 457,219 257,379
Texas (29,216) 8,349 72,921 27,577
Segment EBITDA 831,979 924,992 2,825,019 2,338,957
Corporate expenses (300,274) (269,691) (1,211,764) (1,198,652)
Depreciation and amortization 199,319 235,702 871,967 884,459
Loss on asset disposals, net 26,980 286,562 62,734 317,146
Contested proxy and related matters, net 2,988 - 2,040,810 -
Tornado expenses and write-offs, net - 5,359 (53,755) 368,955
Legal settlement - - 75,000 -
Other income, net 31,623 15,522 132,948 80,230
Interest expense (81,729) (52,657) (229,244) (222,396)
Consolidated $252,312 $90,543 $(1,479,797) $(572,421)
For the year ended
September 29, 2024 October 1, 2023
Depreciation and amortization:
Georgia $357,522 $324,252
Missouri 231,734 275,533
Texas 281,055 283,020
Corporate 1,656 1,654
Consolidated $871,967 $884,459
Capital expenditures:
Georgia $593,515 $1,208,762
Missouri 100,428 134,987
Texas 213,012 214,095
Consolidated $906,955 $1,557,844
As of
September 29, 2024 October 1, 2023
Total assets:
Georgia $7,520,918 $8,519,619
Missouri 3,399,324 3,335,794
Texas 7,812,661 7,698,400
Corporate 461,168 541,910
Consolidated $19,194,071 $20,095,723
Total cash & short-term investments:
Georgia $1,800,623 $3,047,188
Missouri 870,918 671,423
Texas 570,122 312,563
Corporate 82,705 67,213
Consolidated $3,324,368 $4,098,387
Asset less cash & short-term investments:
Georgia $5,720,295 $5,472,431
Missouri 2,528,406 2,664,371
Texas 7,242,539 7,385,837
Corporate 378,463 474,697
Consolidated $15,869,703 $15,997,336


Conference Call and Webcast Details

The Company will host a conference call to review its fiscal year 2024 results on Monday, December 16, 2024, at 4:30 pm ET. The conference call will be webcast and can be accessed on the Company's website, animalsafari.com/investor-relations.

All participants on the conference call will be invited to ask a question. You may also email your question to ralph@parksamerica.com prior to the call. A transcript of the call will be available on the Company's website.

About Parks! America, Inc.

Parks! America, Inc. (OTCPink: PRKA), through our wholly owned subsidiaries, owns and operates three regional safari parks and is in the business of acquiring, developing and operating local and regional entertainment assets in the United States.

Additional information, including our Annual Report on Form 10-K for the fiscal year ended September 29, 2024, is available on the Company's website, animalsafari.com/investor-relations.

Cautionary Note Regarding Forward Looking Statements

This news release may contain "forward-looking statements" within the meaning of U.S. securities laws. Forward-looking statements include statements concerning our future plans, business strategy, liquidity, capital expenditures, sources of revenue and other similar statements that are not historical in nature. You are cautioned not to place undue reliance on these forward-looking statements, which are based on our expectations as of the date of this news release and speak only as of the date hereof. Forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause our actual results to differ significantly from those expressed or implied by such forward-looking statements. Readers are advised to consider the factors listed under the heading "Risk Factors" and the other information contained in the Company's Annual Report on Form 10-K and other reports filed from time to time with the Securities and Exchange Commission. We undertake no obligation to publicly update or revise any forward-looking statements whether as a result of new information, future events or otherwise, except as required by law.

Contact:
Ralph Molina
Head of Investor Relations and Corporate Strategy
(706) 940-2209


© 2024 GlobeNewswire (Europe)
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.